Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and Acceptability.

Philip, J; Wong, A; Pasanen, L; Somogyi, AA; Rubio, J; Klepstad, P; Collins, A; Gibbs, P; Le, B

Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and Acceptability.

Philip, J Wong, A Pasanen, L Somogyi, AA Rubio, J Klepstad, P Collins, A Gibbs, P Le, B

Permalink

Publisher:: MARY ANN LIEBERT, INC
Publication Type:: Journal Article
Citation:: J Palliat Med, 2023, 26, (3), pp. 411-417
Issue Date:: 2023-03

Closed Access

	Filename	Description	Size
	philip-et-al-2023-establishing-a-longitudinal-opioid-pharmacogenomic-registry-for-cancer-patients-feasibility-and.pdf		195.04 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Philip, J
dc.contributor.author	Wong, A
dc.contributor.author	Pasanen, L
dc.contributor.author	Somogyi, AA
dc.contributor.author	Rubio, J
dc.contributor.author	Klepstad, P
dc.contributor.author	Collins, A
dc.contributor.author	Gibbs, P
dc.contributor.author	Le, B https://orcid.org/0000-0002-0830-4864
dc.date.accessioned	2024-01-16T05:15:02Z
dc.date.available	2024-01-16T05:15:02Z
dc.date.issued	2023-03
dc.identifier.citation	J Palliat Med, 2023, 26, (3), pp. 411-417
dc.identifier.issn	1096-6218
dc.identifier.issn	1557-7740
dc.identifier.uri	http://hdl.handle.net/10453/174593
dc.description.abstract	Purpose: Individual genetic variation can affect both pain expression and opioid response. Large cohort datasets are required to validate evidence influencing genomic factors in opioid response. This study examined the feasibility of establishing an opioid pharmacogenomics registry for cancer patients containing longitudinal matched clinical, symptom, pharmacological, and genomic data, with an a priori feasibility target of 50 participants within 12 months. Methods: Consecutive patients with advanced cancer receiving opioids across five palliative care services were recruited. Clinical data (demographics, pain data, adverse effects, medications) and blood (DNA, RNA, pharmacokinetics) were collected over two time points. Patient and clinician qualitative interviews were conducted to assess acceptability. This study was approved by the SVHA Ethics Committee, Melbourne, Australia (HREC 252/18). Results: Enrollment for the registry was deemed feasible. Fifty-eight participants were recruited (median age 63.7, 45% female, 83% complete data), with the most frequent diagnosis being lung cancer (n = 18, 33%) and oxycodone the most frequently prescribed opioid (n = 30, 52%). Qualitative data indicated positive engagement from both patients and clinicians. Conclusion: Establishing a longitudinal opioid pharmacogenomic registry in patients with cancer receiving palliative care is feasible and readily acceptable.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	MARY ANN LIEBERT, INC
dc.relation.ispartof	J Palliat Med
dc.relation.isbasedon	10.1089/jpm.2022.0385
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1110 Nursing, 1117 Public Health and Health Services
dc.subject.classification	Gerontology
dc.subject.classification	4203 Health services and systems
dc.subject.classification	4205 Nursing
dc.subject.mesh	Humans
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Male
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Pharmacogenetics
dc.subject.mesh	Feasibility Studies
dc.subject.mesh	Pain
dc.subject.mesh	Neoplasms
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Pain
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Feasibility Studies
dc.subject.mesh	Pharmacogenetics
dc.subject.mesh	Middle Aged
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Humans
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Male
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Pharmacogenetics
dc.subject.mesh	Feasibility Studies
dc.subject.mesh	Pain
dc.subject.mesh	Neoplasms
dc.title	Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and Acceptability.
dc.type	Journal Article
utslib.citation.volume	26
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1110 Nursing
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
dc.date.updated	2024-01-16T05:15:01Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	26
utslib.citation.issue	3

Abstract:

Purpose: Individual genetic variation can affect both pain expression and opioid response. Large cohort datasets are required to validate evidence influencing genomic factors in opioid response. This study examined the feasibility of establishing an opioid pharmacogenomics registry for cancer patients containing longitudinal matched clinical, symptom, pharmacological, and genomic data, with an a priori feasibility target of 50 participants within 12 months. Methods: Consecutive patients with advanced cancer receiving opioids across five palliative care services were recruited. Clinical data (demographics, pain data, adverse effects, medications) and blood (DNA, RNA, pharmacokinetics) were collected over two time points. Patient and clinician qualitative interviews were conducted to assess acceptability. This study was approved by the SVHA Ethics Committee, Melbourne, Australia (HREC 252/18). Results: Enrollment for the registry was deemed feasible. Fifty-eight participants were recruited (median age 63.7, 45% female, 83% complete data), with the most frequent diagnosis being lung cancer (n = 18, 33%) and oxycodone the most frequently prescribed opioid (n = 30, 52%). Qualitative data indicated positive engagement from both patients and clinicians. Conclusion: Establishing a longitudinal opioid pharmacogenomic registry in patients with cancer receiving palliative care is feasible and readily acceptable.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/174593